The primary goal of the study was to determine if olanzapine is effective in producing weight gain in patients with anorexia nervosa. Twenty patients with anorexia nervosa (restricting or binge/purge subtype) without schizophrenia, schizoaffective disorder, or bipolar disorder enrolled in an open label study of olanzapine 10 mg. Patients attended weekly drug monitoring sessions and weekly group medication adherence sessions that provided psychoeducation. Eighteen patients received the drug and 14 patients completed the 10-week study. The four drop-outs had gained a mean of 3.25 lb at their last visit. Of the 14 patients who completed the study, 10 gained an average of 8.75 lb and 3 of these patients attained their ideal body weight. The remaining four patients who completed the study lost a mean of 2.25 lb. These findings are promising with clinically significant weight gain in an outpatient setting during a brief 10-week period.
Neuroleptics in the short-term treatment of anorexia nervosa. A double-blind placebo-controlled study with sulpiride
Should amenorrhoea be necessary for the diagnosis of anorexia nervosa? Evidence from a Canadian community sample
Structured Interview for Anorexic and Bulimic disorders for DSM-IV and ICD-10: updated (third) revision
Olanzapine plasma concentrations and clinical response: acute phase results of the North American Olanzapine Trial
Tolerability and efficacy of aripiprazole in a case of psychotic anorexia nervosa comorbid with epilepsy and chronic renal failure
Eighty-five per cent of what? Discrepancies in the weight cut-off for anorexia nervosa substantially affect the prevalence of underweight
Evaluation of the efficacy and safety of olanzapine as an adjunctive treatment for anorexia nervosa in adolescent females: a randomized, double-blind, placebo-controlled trial
Eating disorders: an overview of treatment responses and the potential impact of vulnerability genes and endophenotypes
World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of eating disorders
Atypical antipsychotics in severe anorexia nervosa in children and adolescents--review and case reports
Report of the National Institutes of Health workshop on overcoming barriers to treatment research in anorexia nervosa
Expression and activity of P-glycoprotein (MDR1/ABCB1) in peripheral blood mononuclear cells from patients with anorexia nervosa compared with healthy controls
The Role of Psychotropic Medications in the Management of Anorexia Nervosa: Rationale, Evidence and Future Prospects
Pharmacological treatment of acute-phase anorexia nervosa: Evidence from randomized controlled trials
Psychotropic drug treatment in anorexia nervosa. Search for differences in efficacy/tolerability between adolescent and mixed-age population
Differential weight restoration on olanzapine versus fluoxetine in identical twins with anorexia nervosa
Treatment of children and adolescents with avoidant/restrictive food intake disorder: a case series examining the feasibility of family therapy and adjunctive treatments
Anorexia nervosa (AN) is a psychiatric condition characterized by severe weight loss and secondary problems associated with malnutrition. Here is the latest research on AN.
Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here
Bipolar disorder is characterized by manic and/or depressive episodes and associated with uncommon shifts in mood, activity levels, and energy. Discover the latest research this illness here.